RxDoctor Payments Data

Kenneth Backman, MD

Allergy & Immunology · Fairfield, CTNPI 1174595847

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (57.1%), food and beverage and education — rather than concentrated in one kind of arrangement. 27 manufacturers reported payments, led by AstraZeneca at 54.1% of the total. 2025 is the largest year on record at $5,262, 4.4 times the $1,185 reported in 2019.

$11,856in general payments, 2019–2025

Across 268 payments — averaging $44.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$6K
  • Kaleo, Inc.$1K
  • GSK$1K
  • Genentech USA, Inc.$411
  • Boehringer Ingelheim$365
  • Sanofi$256
  • plus $2K from 21 others

What the payments were for

  • Speaking & faculty fees$6,77557%
  • Food & beverage$5,03642%
  • Education$460%

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,856 in reported general payments places this provider in the 80th percentile of 54 allergy & immunology providers in Connecticut.

See all allergy & immunology providers in Connecticut

Medicare billing

Part B allowed, 2024
$68,317
Medicare patients
137
Services billed
5,176

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab14$52,388
TezspireTezepelumab-Ekko11$45,542
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$22,714
Breo ElliptaFluticasone/Vilanterol31$13,529
Breztri AerosphereBudesonide/Glycopyr/Formoterol13$8,372
SymbicortBudesonide/Formoterol Fumarate11$5,186
Epinephrine29$4,605
Mometasone Furoate33$3,665
Azelastine-FluticasoneAzelastine/Fluticasone18$1,927
Montelukast Sodium47$654
Albuterol Sulfate HfaAlbuterol Sulfate19$586
Fluticasone Propionate30$326

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaTezspire, Breztri Aerosphere, Symbicort$6,419$59,10035 claims
GSKTrelegy Ellipta, Breo Ellipta$1,315$36,24347 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 54 allergy & immunology providers in Connecticut.

Other allergy & immunology in Fairfield

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →